Latest news with #Levodopa
Yahoo
5 days ago
- Health
- Yahoo
Small but 'life-changing' policy helps Parkinson's patients who need emergency care at Guelph's hospital
When people go to the emergency department, they're not allowed to take their own medications while they wait, which Theresa Daly says can be a huge problem for people with Parkinson's. A long-time nurse and social worker who actively works in Parkinson's disease support groups, Daly says she's thrilled the hospital in Guelph, Ont., has recently made a tweak to a long-standing practice to make it easier for Parkinson's patients to take their medications on time. "It's life-changing," Daly said. "Life-giving and life-saving and certainly quality of life saving." Hospitals have a policy that any medication given while a person is in the hospital must be through the pharmacy or a physicians order. Hospitals will monitor every patient's medication to avoid mixing, doubling up, choking or even overdosing. But emergency departments can be very busy and this can lead to people not getting medications on time. One of the more common medications for Parkinson's is Levodopa, used to control some of the physical deterioration symptoms. Daly says when a dose is missed, it can lead to people not feeling "normal" again for days, weeks or even months afterwards. The new policy at Guelph General Hospital says, an emergency department nurse is able to give permission to those with Parkinson's to take the medication they brought from home. Daly volunteers with the southwestern Ontario branch of Parkinson Canada and her brother also has the disease. She says she's very familiar with the toll the conditions take on both a sufferer and their loved ones. "To see them move into suffering because they haven't had their medication on time affects two people. The person with Parkinson's and the one who loves them. So it's a big deal," Daly said. Parkinson's disease is a neurological and degenerative condition. It has no cure and can get worse over time. The most commonly known issues from PD include slowness of movement, rigidity, tremors and instability. There are other symptoms associated with the condition including insomnia, anxiety, depression, bladder issues, faintness, leg swelling, heavy sweating, double vision and a multitude of other challenges. Ian Smith has Parkinson's and in the past few months, he's had to go to Guelph General Hospital three times. "[Parkinson's patients] all have different problems, some more than others ... and generally, hospitals don't like you bringing your own pills in," he said. While Smith doesn't always feel drastic effects if he misses a pill, he's familiar with how demanding the medication schedule can be. He takes three pills a day with specific food and timing restrictions. "My little Parkinson pill isn't high on the priority list because nobody has told them that it should be," Smith said. By allowing Parkinson's patients to monitor their medication, he said it's less stress for both them and, he assumes, the medical professionals. Andrea de Jong is the director of the emergency department Guelph General Hospital hospital. She said it's become a successful best practice to give emergency room nurses the power and knowledge to administer medications without having to get an order from a physician. She said there are still restrictions on who is able to administer Parkinson's medication that's brought in from home, but nurses are very familiar with these guidelines. "This ideally helps them go back home quicker and overall have a better experience here," she said. Daly said that Guelph General Hospital was very quick to approve this directive with their emergency department teams and medical advisory committee and said it's in line with much of the work Parkinson Canada aims to do within hospitals. A patient's knowledge of their own rights and their ability to advocate is a separate hurdle, she said. "There's a double prong education piece to this... people with Parkinson's have to know that it was okay, and emerge has to know that they have Parkinson's and that it's important they get their pills on time," Daly said. Parkinson Canada spokesperson Emma Gostovic told CBC News that the organization wasn't aware of any other hospitals in the country with a similar directive for Parkinson's patients and their medications. Most hospitals are still aware this is a concern and are conscious of medication timing, she said. Gostovic called Guelph General Hospital's model one they'd like to "explore and share with others throughout the clinical community."
Yahoo
29-05-2025
- Business
- Yahoo
INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy
INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor symptoms. With the increasing prevalence of Parkinson's globally, the demand for effective treatments is growing. INBRIJA offers a novel, non-oral alternative, positioning it well in the market for patients who struggle with traditional therapies. LAS VEGAS, May 29, 2025 /PRNewswire/ -- DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of INBRIJA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Acorda Therapeutics' INBRIJA (Levodopa) Overview INBRIJA is an inhalable dry powder formulation of levodopa designed for use with the INBRIJA inhaler. The medication is delivered via white hypromellose capsules, each containing 42 mg of levodopa in a spray-dried powder form, along with excipients such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride. Levodopa, the active ingredient in INBRIJA, is an aromatic amino acid with the chemical name (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid. Its molecular formula is C₉H₁₁NO₄, and it has a molecular weight of 197.19 g/mol. INBRIJA is indicated for the intermittent relief of OFF episodes in patients with Parkinson's disease who are already receiving treatment with carbidopa/levodopa. It is not intended to replace regular carbidopa/levodopa therapy but is used to reduce OFF periods and improve motor symptoms. Each therapeutic capsule is used with a specially designed plastic inhaler featuring a blue body, blue cap, and a white mouthpiece. Patients may use INBRIJA up to five times per day, with the maximum daily dose limited to 420 mg. Drug Name INBRIJA (Levodopa) Developer Acorda Therapeutics Approval Year 2018 (US); 2019 (EU) Primary Indication Parkinson's disease Mechanism of action Dopamine receptor agonist Route of administration Oral inhalation Learn more about INBRIJA projected market size for Parkinson's disease @ INBRIJA Market Potential Parkinson's disease is a chronic and progressive neurological condition that primarily affects the ability to control movement. It is caused by the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra—a region vital for regulating voluntary muscle activity. According to DelveInsight, there were approximately 3 million diagnosed prevalent cases of Parkinson's disease across the 7MM in 2024, with the United States accounting for about 45% of these. Although there is currently no cure, symptom management involves a mix of medications and supportive therapies. Treatment typically includes physical, occupational, and speech therapy, and certain patients may benefit from surgical interventions. Complementary therapies are also sometimes used to help manage specific symptoms. Commonly used drugs for Parkinson's include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A receptor antagonists. These medications primarily aim to alleviate motor symptoms, which significantly impact patients' quality of life. DelveInsight estimates the Parkinson's disease market in the 7MM to have been worth USD 3.5 billion in 2024. DelveInsight's analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies. Discover more about the Parkinson's disease market in detail @ Parkinson's Disease Market Report Emerging Competitors of INBRIJA Some of the emerging competitors to INBRIJA in the Parkinson's disease treatment landscape include Solengepras (Cerevance), Buntanetap (Annovis Bio), Prasinezumab (Roche/Protherna), JOTROL (Jupiter Neurosciences), Glovadalen (UCB Biopharma), and others. In April 2025, Cerevance reported that the pivotal Phase III ARISE trial evaluating Solengepras as an adjunctive treatment for Parkinson's disease was ongoing, with topline results expected in the first half of 2026. Cerevance's GPR6 antagonist, Solengepras, did not meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, demonstrating only a modest and statistically non-significant improvement compared to placebo, as reported at AD/PD 2025. According to the results presented at AD/PD 2025, Buntanetap has been shown to prevent cognitive decline across the entire treated ITT population. In patients with existing cognitive impairment, it improved cognitive performance along with MDS-UPDRS, WAIS, and CGI-S scores. A meeting with the US FDA to discuss the future development strategy is scheduled for the second Quarter of 2025. The ATLANTIS Phase II trial design for glovadalen was presented at AD/PD 2025, highlighting its potential as a Parkinson's treatment. As a D1PAM, it boosts dopamine signaling without directly activating receptors. To know more about the number of competing drugs in development, visit @ INBRIJA Market Positioning Compared to Other Drugs Key Milestones of INBRIJA In March 2023, Acorda Therapeutics announced that Esteve Pharmaceuticals launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. Esteve launched INBRIJA in Germany in mid-2022. In September 2019, Acorda Therapeutics announced that the European Commission (EC) granted marketing authorization for INBRIJA 33 mg inhalation powder, hard capsules. In Europe, INBRIJA is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. The Marketing Authorization approves INBRIJA for use in the 28 countries of the European Union, as well as Iceland, Norway, and Liechtenstein. In December 2018, INBRIJA was approved by the US FDA for intermittent treatment of OFF Episodes in people with Parkinson's taking carbidopa/levodopa. Discover how INBRIJA is shaping the Parkinson's disease treatment landscape @ INBRIJA Inhaler INBRIJA Market Dynamics INBRIJA is a medication used to manage "off" periods in patients with Parkinson's disease who are on a stable regimen of oral levodopa. The market dynamics surrounding INBRIJA are influenced by several factors, including the growing demand for innovative treatments for Parkinson's disease, an aging global population, and the increasing recognition of the importance of managing off periods in patients with Parkinson's. As the number of Parkinson's disease patients continues to rise globally, particularly with the aging Baby Boomer generation, the market for Parkinson's disease therapies is expanding, offering significant growth potential for medications like INBRIJA. One of the key drivers for INBRIJA's market is the unmet need for effective treatments for off periods. Traditional oral levodopa, the mainstay of Parkinson's treatment, can lose efficacy over time, leading to motor fluctuations that result in off periods, during which patients experience a worsening of symptoms such as tremors and rigidity. INBRIJA provides an alternative in the form of an inhaled levodopa treatment that acts rapidly to help manage these periods, offering patients a faster-acting option compared to oral medications. This positioning appeals to both patients and healthcare providers who are looking for ways to improve the quality of life for people with Parkinson's. Despite its promising potential, INBRIJA faces challenges in the market. The primary hurdle is its relatively high cost compared to traditional levodopa treatments, which could limit its accessibility, particularly in regions with limited healthcare resources. Additionally, the need for an inhaler device and potential issues related to device handling and patient compliance could also impact market penetration. Moreover, INBRIJA competes with other therapeutic options in the Parkinson's space, including dopamine agonists and other adjunctive treatments, which means ongoing education and marketing efforts are required to differentiate its unique benefits. In terms of market opportunities, INBRIJA could benefit from increased awareness among healthcare providers about the drug's role in improving patient outcomes during off periods. Collaborations with Parkinson's disease advocacy groups and patient education initiatives could help drive adoption. Furthermore, expanding indications or seeking approval for additional uses could open up new revenue streams and bolster INBRIJA's position in the Parkinson's treatment market. Overall, while the market for INBRIJA faces challenges, the growing demand for better management of Parkinson's symptoms presents opportunities for continued growth and adoption. Dive deeper to get more insight into INBRIJA's strengths & weaknesses relative to competitors @ INBRIJA Market Drug Report Table of Contents 1 Report Introduction 2 INBRIJA: Acorda Therapeutics 2.1 Product Overview 2.2 Other Development Activities 2.3 Clinical Development 2.4 Clinical Trials Information 2.5 Safety and Efficacy 2.6 Product Profile 2.7 Market Assessment 2.7.1 The 7MM Analysis 2.7.1.1 Cost Assumptions and Rebate 2.7.1.2 Pricing Trends 2.7.1.3 Analogue Assessment 2.7.1.4 Launch Year and Therapy Uptake 2.7.2 The United States Market Analysis 2.7.3 EU4 and the United Kingdom Market Analysis 2.7.3.1 Germany 2.7.3.2 France 2.7.3.3 Italy 2.7.3.4 Spain 2.7.3.5 UK 2.7.4 Japan Market Analysis 2.8 Market Drivers 2.9 Market Barriers 2.10 SWOT Analysis 3 Key Cross of Marketed Competitors of INBRIJA 4 Key Cross of Emerging Competitors of INBRIJA Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others. Parkinson's Disease Pipeline Parkinson's Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others. Cell and Gene Therapy in Parkinson's Disease Market Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others. Parkinson's Disease Psychosis Market Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Sign in to access your portfolio
Arab Times
17-04-2025
- Health
- Arab Times
First-of-its-kind treatment offers a new lease on life for the youngest Parkinson's patient in the UAE and MENA region.
In a remarkable advancement in medical care, King's College Hospital London in Dubai has successfully administered the subcutaneous Levodopa (Fos-levodopa) pump treatment to the youngest Parkinson's patient in the UAE and the broader Middle East, North Africa (MENA), and GCC regions. Diagnosed with Parkinson's disease at just 30 years old, the patient has been battling the condition for 14 years and previously relied on continuous support from three caregivers. This groundbreaking treatment marks a significant milestone in Parkinson's care, offering renewed hope and a notable improvement in the patient's quality of life. As one of the leading facilities for advanced neurological and Parkinson's care in the region, King's College Hospital Dubai is proud to be among the first to offer the Foslevodopa pump—an innovative next-generation treatment for advanced Parkinson's disease. This procedure delivers levodopa, the gold standard in Parkinson's treatment, continuously through the skin, similar to an insulin pump used for diabetes management. The treatment is personalized to meet the individual needs of each patient, with medication doses adjusted by experienced Parkinson's specialists such as Dr. Vinod Metta and Prof. Ray Chaudhuri. The new solution transforms Parkinson's care in the UAE, enabling patients to regain their independence and participate in daily activities, such as fasting during Ramadan, after years of struggle. "Personalized care and tailored dosage are essential in Parkinson's treatment, as each patient's condition is unique. It is important to optimize the dosage based on disease severity and the patient's dopamine requirements. With device-assisted therapies like the Foslevodopa pump, patients can take control of their condition. Watching our patient regain independence, enjoy a meal on his own, and walk unaided is a powerful testament to the positive impact this new treatment can have on individuals' lives." The procedure was carried out at the Parkinson's Centre of Excellence at King's College Hospital London in Dubai, a regional leader in movement disorder care. The center is dedicated to offering world-class diagnostics, treatment innovations, and multidisciplinary support to Parkinson's patients and their families, ensuring holistic, patient-centered care. Professor Ray Chaudhuri, Professor of Neurology and Movement Disorders at King's College Hospital London, highlighted the significance of this breakthrough: "This is a transformative moment for Parkinson's care in the region. Introducing Foslevodopa at King's Dubai represents a major leap forward in personalized therapy, ensuring patients receive optimal care. This groundbreaking breakthrough further reinforces King's commitment to being at the forefront of neurological advancements." King's Parkinson's Centre of Excellence: Leading the Future of Parkinson's Care * A Centre of Excellence for Parkinson's Disease in Dubai/UAE * World-renowned UK-trained Parkinson's specialists, led by Dr. Vinod Metta and Prof. Ray Chaudhuri * Bespoke and tailored approaches, supported by a multidisciplinary team of specialists, including Parkinson's nurses, physiotherapists, speech therapists, dieticians, neuroradiologists, and occupational therapists * King's Parkinson's Centre of Excellence in Dubai started with just one patient under Dr. Vinod Metta's leadership and has since grown into a well-known tertiary referral center in the UAE, Middle East, and MENA, treating over 1,000 Parkinson's patients across the GCC For more information about the Foslevodopa/Foscarbidopa pump treatment, please contact King's Parkinson's Centre of Excellence. Our Parkinson's Nurse Specialist will be happy to assist with any inquiries: * Ms. Therese Masagnay: [email protected] * Ms. Clarissa Sanglian: Clarissa
Khaleej Times
07-04-2025
- Health
- Khaleej Times
Dubai unveils new Parkinson's Pump at King's College Hospital London in Dubai
First-of-its-kind treatment offers a new lease on life for the youngest Parkinson's patient in the UAE and Mena region In a remarkable advancement in medical care, King's College Hospital London in Dubai has successfully administered the subcutaneous Levodopa (Fos-levodopa) pump treatment to the youngest Parkinson's patient in the UAE and the broader Middle East, North Africa (MENA), and GCC regions. Diagnosed with Parkinson's disease at just 30 years old, the patient has been battling the condition for 14 years and previously relied on continuous support from three caregivers. This groundbreaking treatment marks a significant milestone in Parkinson's care, offering renewed hope and a notable improvement in the patient's quality of life. As one of the leading facilities for advanced neurological and Parkinson's care in the region, King's College Hospital Dubai is proud to be among the first to offer the Foslevodopa pump - an innovative next-generation treatment for advanced Parkinson's disease. This procedure delivers levodopa, the gold standard in Parkinson's treatment, continuously through the skin, similar to an insulin pump used for diabetes management. The treatment is personalized to meet the individual needs of each patient, with medication doses adjusted by experienced Parkinson's specialists such as Dr. Vinod Metta and Prof. Ray Chaudhuri. The new solution transforms Parkinson's care in the UAE, enabling patients to regain their independence and participate in daily activities - such as fasting during Ramadan - after years of struggle. Dr Vinod Metta, Consultant Interventional Neurologist & Parkinson's Specialist at King's College Hospital London, Dubai, expressed his thoughts on the successful treatment: "Personalised care and tailored dosage are essential in Parkinson's treatment, as each patient's condition is unique. It is important to optimize the dosage based on disease severity and the patient's dopamine requirements. With device-assisted therapies like the Foslevodopa pump, patients can take control of their condition. Watching our patient regain independence, enjoy a meal on his own, and walk unaided is a powerful testament to the positive impact this new treatment can have on individuals' lives." The procedure was carried out at the Parkinson's Centre of Excellence at King's College Hospital London in Dubai, a regional leader in movement disorder care. The center is dedicated to offering world-class diagnostics, treatment innovations, and multidisciplinary support to Parkinson's patients and their families, ensuring holistic, patient-centered care. Professor Ray Chaudhuri, Professor of Neurology and Movement Disorders at King's College Hospital London, highlighted the significance of this breakthrough: "This is a transformative moment for Parkinson's care in the region. Introducing Foslevodopa at King's Dubai represents a major leap forward in personalized therapy, ensuring patients receive optimal care. This groundbreaking breakthrough further reinforces King's commitment to being at the forefront of neurological advancements." King's Parkinson's Centre of Excellence: Leading the Future of Parkinson's Care ● A Centre of Excellence for Parkinson's Disease in Dubai/UAE ● World-renowned UK-trained Parkinson's specialists, led by Dr. Vinod Metta and Prof. Ray Chaudhuri ● Bespoke and tailored approaches, supported by a multidisciplinary team of specialists, including Parkinson's nurses, physiotherapists, speech therapists, dieticians, neuroradiologists, and occupational therapists ● King's Parkinson's Centre of Excellence in Dubai started with just one patient under Dr. Vinod Metta's leadership and has since grown into a well-known tertiary referral center in the UAE, Middle East, and MENA, treating over 1,000 Parkinson's patients across the GCC For more information about the Foslevodopa/Foscarbidopa pump treatment, please contact King's Parkinson's Centre of Excellence. Our Parkinson's Nurse Specialist will be happy to assist with any inquiries: This advancement represents a significant step forward in improving Parkinson's care and offering hope to patients in the UAE and beyond.
